

## Supplementary material

**Supplementary Table 1.** Immunosuppressant treatments during follow-up

	Time post-transplant							
	1 month	3 months	6 months	12 months	2 years	3 years	4 years	5 years
<b>Tacrolimus</b>								
N	279	272	270	265	241	195	140	85
Immediate-release tacrolimus, n (%)	168 (60.2)	151 (55.5)	131 (48.5)	121 (45.7)	98 (40.7)	80 (41.0)	52 (37.1)	27 (31.8)
Prolonged-release tacrolimus, n (%)	110 (39.4)	121 (44.5)	138 (51.1)	143 (54.0)	141 (58.5)	113 (57.9)	85 (60.7)	57 (67.1)
Dose (mg/day), mean	8.2	7.4	6.8	5.9	5.0	4.6	4.3	4.2
Trough levels (ng/mL), mean	10.8	10.3	9.3	8.5	11.1	8.0	7.2	7.2
<b>Mycophenolate mofetil</b>								
N	279	273	270	265	241	195	139	85
MMF, n (%)	151 (54.1)	141 (51.6)	129 (47.8)	120 (45.3)	109 (45.2)	84 (43.1)	63 (45.3)	42 (49.4)
MFA, n (%)	125 (44.8)	128 (46.9)	134 (49.6)	138 (52.1)	123 (51.0)	100 (51.3)	67 (48.2)	38 (44.7)

	Time post-transplant							
	1 month	3 months	6 months	12 months	2 years	3 years	4 years	5 years
<b>mTOR inhibitors</b>								
N	200	200	200	182	176	143	103	63
Sirolimus, n (%)	1 (0.5)	2 (1.0)	1 (0.5)	2 (1.1)	3 (1.7)	4 (2.8)	4 (3.9)	2 (3.2)
Everolimus, n (%)	0	0	1 (0.5)	1 (0.5)	3 (1.7)	4 (2.8)	2 (1.9)	1 (1.6)
<b>Other immunosuppressants</b>								
N	289	286	280	272	244	197	144	87
Azathioprine, n (%)	1 (0.3)	2 (0.7)	2 (0.7)	3 (1.1)	2 (0.8)	3 (1.5)	5 (3.5)	5 (5.7)
Prednisone, n (%)	280 (96.9)	272 (95.1)	264 (94.3)	244 (89.7)	206 (84.4)	161 (81.7)	111 (77.1)	65 (74.7)

MMA, mycophenolic acid; MMF, mycophenolate mofetil; mTOR, mammalian target of rapamycin; N, number of patients with available data; n, number of patients receiving a given therapy; SD, standard deviation. Percentages were calculated based on the number of patients with available data

**Supplementary Table 2.** Treatments for hypertension during follow-up

	Time post-transplant								
	At transplant	1 month	3 months	6 months	12 months	2 years	3 years	4 years	5 years
N	301	289	286	280	272	244	197	144	87
ACEi, n (%)	50 (16.6)	5 (1.7)	11 (3.8)	18 (6.4)	19 (7.0)	16 (6.6)	15 (7.6)	11 (7.6)	7 (8.0)
ARB, n (%)	144 (47.8)	38 (13.1)	48 (16.8)	51 (18.2)	64 (23.5)	69 (28.3)	54 (27.4)	43 (29.9)	28 (32.2)
Beta blockers, n (%)	70 (23.3)	60 (20.8)	59 (20.6)	57 (20.4)	57 (21.0)	50 (20.5)	49 (24.9)	32 (22.2)	19 (21.8)
Alpha blockers, n (%)	72 (23.9)	20 (6.9)	20 (7.0)	22 (7.9)	17 (6.3)	18 (7.4)	15 (7.6)	12 (8.3)	7 (8.0)
Diuretics, n (%)	82 (27.2)	22 (7.6)	20 (7.0)	18 (6.4)	14 (5.1)	12 (4.9)	15 (7.6)	9 (6.3)	5 (5.7)
Calcium antagonists, n (%)	140 (46.5)	69 (23.9)	71 (24.8)	56 (20.0)	60 (22.1)	55 (22.5)	50 (25.4)	35 (24.3)	16 (18.4)

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker

### Supplementary Figure 1. Subject disposition over the 5-year observation period after pancreas transplantation

